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Abstract 
Objective
Topiramate is effective in the prevention of pediatric migraine, and 
studies show that vitamin D3 supplementation might also be useful 
in the treatment of adult migraineurs with a normal vitamin D3 level. 
The present study aimed at comparing the efficacy and safety of 
topiramate plus vitamin D3 and topiramate alone in the prophylaxis 
of pediatric migraine.
Materials & Methods
In a single-blinded, randomized, clinical trial, 5-15-year-old children 
with migraine headaches, referred to the Pediatric Neurology Clinic 
of Shahid Sadoughi Medical Sciences University, Yazd, Iran from 
January 2016 to January 2017, were randomly allocated to receive 
2 mg/kg/day of topiramate or 2 mg/kg/day of topiramate plus one 
500,000 IU vitamin D3 pearl weekly for two consecutive months.
Primary outcomes were the reduction of monthly frequency, severity, 
duration, and the disability score of migraine, and the secondary 
outcomes included a good response to treatment (more than 50% 
reduction in monthly headache frequency) and a lack of clinical 
adverse events.
Results
Totally, 31 female and 26 male children with the mean age of 
10.02±2.11 years were evaluated. Both drugs were effective in the 
reduction of monthly frequency, severity, duration, and disability for 
headaches. Nevertheless, the combination of topiramate and vitamin 
D3 was more effective than topiramate alone in reducing the monthly 
headaches frequency (6.12±1.26 vs. 9.87±2.44 times, P=0.01) and 
disability score (19.24±6.32 vs. 22.11±7.91, P=0.02). Good response 
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to treatment was observed in 60.7% and 75.9% of the subjects 
in the topiramate alone and topiramate plus vitamin D3 groups, 
respectively, and topiramate plus vitaminD3 was more effective (P= 
0.01). Transient mild side effects were observed in 14.3% and 17.2% 
of the subjects in the topiramate alone and topiramate plus vitamin D3 
groups, respectively (P=0.8).
Conclusion
A combination of Topiramate and vitamin D3 might be considered 
safe and more effective than Topiramate alone in the prophylaxis of 
pediatric migraine.
Keywords: Migraine, Child, Prophylaxis, Vitamin D3, Topiramate 
Introduction
Migraine, as the most common primary headache 
in children, occurs in up to 10.6% of the 5-15-year-
old children and migraine prophylaxis should be 
started if headache episodes occur more than once a 
week or the disability score is higher than 20 based 
on the pediatric migraine disability assessment 
scale (ped MIDAS)(1). There is no unique 
guideline for the prophylaxis of pediatric migraine, 
although the US Food and Drug Administration 
has approved flunarizine and, recently, topiramate 
for migraine prophylaxis in pediatric patients (2), 
and topiramate, as a safe and effective drug, should 
be strongly encouraged for migraine prevention in 
children (3).
Today, physicians are interested in using alternative 
medicine and non-pharmacological remedies for 
migraine prevention, and many nutraceutics, such 
as magnesium, coenzyme Q10, riboflavin, butterbur, 
feverfew, melatonin, etc., are utilized for the 
prophylaxis of migraine in children and adults (4). 
Vitamin D3 deficiency (serum 25-hydroxyvitamin 
D3 or 25-OH vitamin D3 level <20 ng/mL) 
and insufficiency (25-OH vitamin D3 <30 ng/
mL) are worldwide public health issues (5) that 
can influence all body organs with different 
complications, including myopathies, cancers, skin, 
musculoskeletal, autoimmune, cardiovascular, and 
kidney diseases, as well as mental disorders, such 
as depression and schizophrenia (6,7). In a study 
in Tehran, Iran, 86% of 9-12-year-old children had 
vitamin D3 deficiency (8). 
Association between the dysfunction of transporter 
proteins of vitamin D3 metabolites and migraine 
attacks was observed in a study by Nagata et al. 
(9), and that higher levels of vitamin D3 might 
reduce the risk of migraine headaches. In some 
researches, patients with non-migraine headaches 
had low serum levels of 25-hydroxyvitamin D3 (7, 
10, 11). Association between migraine and serum 
25-hydroxyvitamin D3 level was not observed in 
some studies (10, 12, 13). However, in a study in 
Isfahan, Iran, a positive relationship was observed 
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between serum levels of vitamin D3 and migraine 
(14), and in another study in Tehran, adult 
migraineurs had a lower serum vitamin D3 level and 
vitamin D3 deficiency, and insufficiency was more 
frequent in them compared to healthy controls. It 
was concluded that the increase in serum levels 
of 25-hydroxyvitamin D3 might decrease the risk 
of migraine headaches (15). In a study in Turkey, 
serum vitamin D3 level was lower in patients with 
migraine (16). Association between the prevalence 
of migraine and the latitude was observed, and the 
higher latitude had a higher one-year prevalence 
for migraine. Moreover, the presence of vitamin 
D receptor, 1alpha-hydroxylase, and vitamin 
D-binding protein in the hypothalamus was 
suggestive of the role of vitamin D3 deficiency in 
the incidence of migraine headaches (17).
A randomized clinical trial by Gazerani et al., 
showed the prophylactic efficacy of 100 μg/day 
supplement of vitamin D3 for the prevention of 
migraine in 18-65-year-old migraineurs, and the 
drug was more effective than placebo in decreasing 
daily headache episodes and frequency, and 25-
OH vitamin D3 levels significantly increased in 
the vitamin D3 group during the first 12 weeks of 
treatment (18).
The efficacy of vitamin D3 therapy in adult 
migraineurs (19, 20), as well as 8-16-year-old 
children with migraine headaches (21), was reported 
in a few research and there is limited efficacy 
evidence of vitamin D3 therapy in the prophylaxis 
of pediatric migraine. Further randomized clinical 
trials are required to evaluate this issue.
The present study aimed at answering the question 
that whether or not topiramate plus vitamin D3 is 
more efficient than topiramate alone in reducing 
the monthly frequency, severity, and the disability 
score in 5-15-year-old migraineur children without 
vitamin D3 deficiency.
Materials & Methods
In a randomized, single-blind, clinical, open-
label, parallel-group study, the efficacy of 
topiramate alone and topiramate plus vitamin 
D3 was compared in the prophylaxis of migraine 
headaches of 5-15-year-old children without 
vitamin D3 deficiency, referred to the Pediatric 
Neurology Clinic of Shahid Sadoughi Medical 
Sciences University, Yazd, Iran from January 2016 
to January 2017. All participants were the Yazd 
City inhabitants and equally exposed to direct 
sunlight.
A more than 50% decrease in the monthly headache 
frequency during the follow-up period was defined 
as a good response to treatment. The sample size 
was determined 30 in each group using the Z 
formula, based on the confidence interval (CI) of 
95%, power of 80%, type I error of 5%, and the 
effect size (difference in the frequency of good 
response between the two groups) of 30% for the 
primary endpoint. 
Inclusion criteria were: children aged 5-15 years 
with migraine headaches based on the International 
Headache Society Criteria (22), one or more 
headache attacks per week, moderate or severe 
disability for headaches or the PedMIDAS score 
>20 (23), normal hemoglobin (Hb) level and mean 
corpuscular volume (Hb level >11.5 g/dL, mean 
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corpuscular volume >80 fL), sufficient vitamin D3 
serum level (>30 ng/mL), not taking vitamin D3 
supplements within the past two months, and not 
receiving any migraine preventive therapies.
Exclusion criteria were: the presence of systemic 
diseases (renal, cardiac, hepatic, hemostatic, 
diabetes mellitus, etc.) based on clinical and 
laboratory screening evaluations, headaches other 
than migraine or secondary headaches, excessive 
drugs usage, discontinuation of drugs for more 
than one week, allergy to topiramate or vitamin D3, 
and vitamin D3 serum level of >80 ng/mL.
The trial used computer-generated random 
numbers for the simple randomization of subjects, 
and the allocation ratio was 1:1 for the two groups. 
Randomization and blinding were performed by 
an investigator not clinically involved in the trial. 
Data collectors, outcome assessors, data analysts, 
and the staff delivering the intervention were blind 
to the allocation. The drug was delivered by the 
nurse of the clinic and was packed and labeled 
according to a medication code schedule generated 
before the trial. Inside all packages, the amount of 
the drug in one tablet and its dosage were written. 
After opening the packages, the drug dosage was 
determined by the pediatric neurologist, based on 
the weight of the child. Primary and secondary 
outcomes were assessed by the pharmacy student 
of the research not aware of the drug group 
assignment.
Totally, 60 children were randomly assigned to 
two groups to receive 2 mg/kg/day of topiramate 
or 2 mg/kg/day of topiramate plus one 500,000 
IU vitamin D3 pearl weekly for two consecutive 
months. In the current study, 500,000 IU vitamin 
D3 pearls and 25 and 50 mg topiramate tablets were 
purchased from Daroupakhsh Co., Iran.
The patients were visited weekly for two 
consecutive months by the pharmacy student of the 
research in the Pediatric Neurology Clinic of Shahid 
Sadoughi Hospital and clinical information about 
frequency, severity, and duration of headaches, the 
pedMIDAS score (23), and frequency and severity 
of clinical side effects of the drugs were recorded 
by interviewing the mothers and reviewing self-
reported diaries and daily notes of parents. The 
severity of headaches was assessed by asking each 
child to grade the majority of headache pain on the 
11-point visual analogue scale (VAS) (24) from 0 
as no pain to 10 as the most severe pain. The VAS 
is a 10-cm long horizontal or vertical line, marked 
at the ends with no pain and worst pain imaginable, 
and the child is asked to place a mark on the line 
that represents his pain level. 
Safety evaluation included spontaneous reports 
of side effects, physical exam, and assessment 
of vital signs. Parents were requested to call the 
researcher promptly if serious adverse events (i.e., 
refractory nausea or vomiting, topiramate-related 
heatstroke, drug rashes with eosinophilia and 
systemic symptoms, severe anorexia and weight 
loss, difficulties with concentration, behavior 
changes, abdominal pain or renal colic, lethargy, 
and disorientation) occurred.
Throughout the research, analgesics (acetaminophen 
or ibuprofen) were permitted for the symptomatic 
relief of moderate to severe headache attacks.
The drugs were continued for 60 consecutive 
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days and, then, monthly frequency, severity, and 
duration of headaches, and the pedMIDAS scores 
before and after three months of intervention were 
compared. A more than 50% reduction in monthly 
headaches frequency was considered as a good 
response to treatment.
Primary outcomes were the frequency of good 
response to treatment (more than 50% reduction 
in monthly headaches frequency), and reduction 
in severity, duration, and disability for headaches. 
The secondary outcome was the clinical side 
effects of drugs.
The data were analyzed in SPSS version 17. The 
Chi-squared or Fisher exact test was used for the 
data analysis of qualitative variables, and mean 
values were compared by t-test. Differences were 
considered significant at P-values <0.05.
Informed consent was taken from parents before 
the administration of drugs, and the study protocol 
was approved by the Ethics Committee of Shahid 
Sadoughi University of Medical Sciences. The 
study was not funded by any pharmaceutical 
companies. The current study was registered in 
the Iranian Registry of Clinical Trials (registration 
number: IRCT201701092639N20).
Results 
Two children in the topiramate alone and one in the 
topiramate plus vitamin D3 groups discontinued 
drug usage during the follow-up period, and 
finally, the trial was completed with 57 children, 
31 females (45.6%) and 26 males (54.4%), with 
the mean age of 10.02 ± 2.11 years.
The comparison of some characteristics of the 
children in both groups is shown in Table 1, 
indicating that age and gender distribution, as well 
as the type and positive family history of migraine, 
were not significantly different between the two 
groups.
Table 2 shows the comparison of headaches 
characteristics before treatment between the two 
groups, indicating that the monthly frequency, 
severity, duration, and disability for headaches 
were not significantly different between the groups.
Comparisons of headaches characteristics before 
and after the treatment in the topiramate alone and 
topiramate plus vitamin D3 groups are presented 
in tables 3 and 4, showing that both drugs were 
effective in the reduction of monthly frequency, 
severity, duration, and disability for headaches.
Table 5 shows the comparison of headaches 
characteristics after treatment, indicating that 
topiramate plus vitamin D3 was more effective 
than topiramate alone in the reduction of monthly 
frequency and disability score. The severity and 
duration of headaches were not significantly 
different between the two groups.
After eight weeks of treatment, good response 
(more than 50% reduction in the frequency of the 
monthly headaches) was observed in 17 children 
in the topiramate alone (60.7%; 95%CI: 42.93%-
79.07%) and 22 subjects in the topiramate plus 
vitamin D3 (75.9%; 95%CI: 60.46%- 91.54%) 
groups, and topiramate plus vitamin D3 was 
significantly more effective (P=0.01).
Clinical side effects were observed in 14.3% (n=4) 
of the topiramate alone group subjects, including 
daily sleepiness in two, anorexia in one, and 
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Table 1. Comparison of the Characteristics of Children in the Study Groups 
Group
Data 
Topiramate Alone Topiramate Plus Vitamin D3 P-value
Age, yr (mean ± SD) 10.67 ± 2.11 10.33 ± 2.45 0.79
Gender Female 16 15 0.7
Male 12 14
Type of migraine Without aura 20 19 0.9
With aura 8 10
Positive family history 
of migraine
Yes 22 24 0.8
No 6 5







Monthly headaches frequency (mean ±SD) 12.98±3.98 13.43±4.11 0.5
The severity of headaches (mean ±SD) 6.97±2.11 6.82 ± 2.9 0.9
Headaches duration, (mean ±SD) 2.31 ± 0.52 2.22 ± 0.63 0.6
Disability for headaches: pedMIDAS score (mean ±SD) 32.12 ± 8.89 32.23 ± 9.45 0.7








Monthly headaches frequency 12.98±3.98 9.87 ± 2.44 0.01
The severity of headaches 6.97±2.11 4.89 ± 2.01 0.04
Headaches duration 2.31 ± 0.52 1.39 ± 0.11 0.01
Disability for headaches: pedMIDAS score 32.12 ± 8.89 22.11 ± 7.91 0.001
difficulty with concentration in one child, and 
in 17.2% (n=5) of the patients in the topiramate 
plus vitamin D3 group, including daily sleepiness 
in two, constipation in two, and anorexia in one 
child. The safety of both drugs had no significant 
difference (P =0.8). All the adverse effects were 
transient and disappeared in one or two weeks, and 
treatment was stopped in none of the patients who 
developed side-effects. 
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Discussion 
 Many drugs are used for the prophylaxis of 
pediatric migraine. In the study by Wheeler et al., 
40.7% of the patients with chronic migraine had 
vitamin D3 deficiency (25). Exposure of arms and 
legs or arms and face two or three times per week 
to direct sunlight can be associated with a sufficient 
vitamin D3 level. Nevertheless, many factors, 
including age, obesity, melanin level, application 
of sunscreens, wearing covered dresses, drugs, time 
of the day, latitude, and sun exposure through glass 
can change the production of vitamin D in the skin. 
Hyperthyroidism and hypothyroidism can also 
severely affect the vitamin D3 level (26). Vitamin 
D3 may have a role in the secretion of serotonin 
and dopamine, while the two neurotransmitters 
are involved in migraine pathogenesis. Vitamin 
D receptors present in the hypothalamus, as 
a region for migraine pain sensation, and the 
neuroprotective and antioxidant effects of vitamin 
D3 in the central nervous system can support the 
relationship between vitamin D3 and prophylaxis 
of migraine (21, 27). Association between low 
serum levels of vitamin D3 and more incidence of 
chronic headaches, and the effectiveness of vitamin 
D3 in the treatment of a few headache disorders are 
reported (7, 17, 28, 29). 
Some studies reported that the incidence of 
migraine attacks increases during autumn and 
winter in children, or a seasonal change in vitamin 
D3 level is correlated with an increase in migraine 
attacks, which mostly occurs in winter (17, 21, 30). 
In the present study, the efficacy and safety of 
topiramate plus vitamin D3 and topiramate alone 








Monthly headaches frequency 13.43±4.11 6.12±1.26 0.001
The severity of headaches 6.82 ± 2.9 4.72 ± 1.99 0.01
Headaches duration, h 2.22 ± 0.63 1.44 ± 0.86 0.0001
Disability for headaches: pedMIDAS score 32.23 ± 9.45 19.24 ± 6.32 0.0001





Topiramate Plus Vitamin D3
(Mean ±SD)
P-value
Monthly headaches frequency 9.87 ± 2.44 6.12±1.26 0.01
The severity of headaches 4.89 ± 2.01 4.72 ± 1.99 0.5
Headaches duration 1.39 ± 0.11 1.44 ± 0.86 0.1
Disability for headaches: 
pedMIDAS score
22.11 ± 7.91 19.24 ± 6.32 0.02
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in the prophylaxis of pediatric migraine were 
compared.  
Based on the results of the present study, the 
combination of 2 mg/kg topiramate and 500,000 IU 
vitamin D3 weekly for two consecutive months was 
more effective than topiramate alone in reducing 
the monthly frequency and disability score of 
migraine in 5-15-year-old children without vitamin 
D3 insufficiency (serum 25-OH vitamin D3 >30 ng/
mL). Also, in a Turkish study, the combination 
of 1 mg/kg amitriptyline and 400 IU per day 
vitamin D3 for six months was more effective than 
amitriptyline alone in headaches frequency of 
6-18-year-old children with migraine and normal 
serum 25-OH vitamin D3 level (>20 ng/mL) (21).
The limitations of the present study were lack of 
placebo, short duration of treatment, and lack of 
follow-up after discontinuation. 
In Conclusion 
Results of the current study showed that the 
combination of topiramate and vitamin D3 was more 
effective than topiramate alone in the reduction 
of monthly frequency and the disability score of 
migraine in children, and vitamin D3 therapy might 
be considered a safe and effective strategy for the 
prophylaxis of pediatric migraine. Further clinical 
trials with larger sample sizes, altitude control, and 
seasonal differences are required to determine the 
optimal dose of vitamin D3 for the prevention of 
pediatric migraine. 
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